Nanobiotix (NBTX) News Today $22.18 -0.44 (-1.95%) Closing price 04:00 PM EasternExtended Trading$22.62 +0.45 (+2.01%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NBTX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Nanobiotix (NASDAQ:NBTX) Sees Large Volume Increase - Still a Buy?October 20 at 4:16 PM | marketbeat.comNanobiotix S.A. - Sponsored ADR (NASDAQ:NBTX) Sees Large Growth in Short InterestOctober 18, 2025 | marketbeat.comNanobiotix (NASDAQ:NBTX) Shares Gap Down - Here's What HappenedOctober 15, 2025 | marketbeat.comNanobiotix (NASDAQ:NBTX) Hits New 52-Week High - Here's What HappenedOctober 14, 2025 | marketbeat.comNanobiotix (NASDAQ:NBTX) Trading Up 19.2% - Here's WhyOctober 13, 2025 | marketbeat.comNanobiotix (NASDAQ:NBTX) Shares Down 12% - Should You Sell?October 11, 2025 | marketbeat.comStifel Nicolaus Remains a Buy on Nanobiotix (0QAV)October 10, 2025 | theglobeandmail.comNanobiotix (NASDAQ:NBTX) Sees Unusually-High Trading Volume - Here's WhyOctober 10, 2025 | marketbeat.comWeiss Ratings Reiterates "Sell (D-)" Rating for Nanobiotix (NASDAQ:NBTX)October 10, 2025 | marketbeat.comThis Stock Is Up 440% in a Year. Is It an Undiscovered Star or a Flash in the Pan?October 9, 2025 | msn.comJefferies Reaffirms Their Buy Rating on Nanobiotix (0QAV)October 8, 2025 | theglobeandmail.comNanobiotix (NASDAQ:NBTX) Shares Gap Up - Here's WhyOctober 8, 2025 | marketbeat.comNanobiotix (NASDAQ:NBTX) Shares Gap Down - Here's WhyOctober 7, 2025 | marketbeat.comNanobiotix (NASDAQ:NBTX) Reaches New 12-Month High - Should You Buy?October 6, 2025 | marketbeat.comFY2027 EPS Estimates for Nanobiotix Boosted by HC WainwrightOctober 6, 2025 | marketbeat.comLeerink Partners Sticks to Its Buy Rating for Nanobiotix (NBTX)October 4, 2025 | theglobeandmail.comShort Interest in Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX) Decreases By 53.2%October 3, 2025 | marketbeat.comNanobiotix Reveals Promising Phase 1 Results for JNJ-1900 in Cancer TreatmentOctober 2, 2025 | theglobeandmail.comNanobiotix Shares Surge After Encouraging Esophageal Cancer Study ResultsOctober 2, 2025 | msn.comNanobiotix (NASDAQ:NBTX) Shares Gap Up - Still a Buy?October 2, 2025 | marketbeat.comNANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal CancerOctober 1, 2025 | globenewswire.comNanobiotix stock soars after promising cancer treatment resultsSeptember 30, 2025 | za.investing.comNanobiotix-J&J Therapy Shows Promise In Tough Head And Neck CancerSeptember 30, 2025 | uk.finance.yahoo.comNanobiotix Releases Half-Year Financial Report Highlighting JNJ-1900 DevelopmentsSeptember 30, 2025 | msn.comNanobiotix Reports Half-Year 2025 Financial Results and Strategic ProgressSeptember 30, 2025 | msn.comNANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial ResultsSeptember 30, 2025 | globenewswire.comNanobiotix (NASDAQ:NBTX) Reaches New 1-Year High - Here's WhySeptember 30, 2025 | marketbeat.comNANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCCSeptember 29, 2025 | globenewswire.comNanobiotix (NASDAQ:NBTX) Sees Unusually-High Trading Volume - Should You Buy?September 29, 2025 | marketbeat.comNanobiotix (NASDAQ:NBTX) Shares Gap Down - What's Next?September 25, 2025 | marketbeat.comNanobiotix (NASDAQ:NBTX) Hits New 52-Week High - Here's WhySeptember 23, 2025 | marketbeat.comNanobiotix (NASDAQ:NBTX) Trading 11.8% Higher - Time to Buy?September 22, 2025 | marketbeat.comNanobiotix price target raised to $14 from $9 at LeerinkSeptember 20, 2025 | msn.comNanobiotix (NASDAQ:NBTX) Sees Large Volume Increase - Here's What HappenedSeptember 20, 2025 | marketbeat.comNanobiotix (NBTX) Projected to Post Earnings on MondaySeptember 20, 2025 | marketbeat.comNanobiotix price target raised to EUR 13 from EUR 10 at H.C. WainwrightSeptember 19, 2025 | msn.comNanobiotix (NASDAQ:NBTX) Shares Gap Up - Should You Buy?September 19, 2025 | marketbeat.comShort Interest in Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX) Grows By 23.7%September 19, 2025 | marketbeat.comMelanoma Data Study Boosts J&J Partner Nanobiotix Stock On ThursdaySeptember 18, 2025 | benzinga.comNanobiotix: Today's Data Readout For Radiation Therapy Enhances Bull CaseSeptember 18, 2025 | seekingalpha.com4 Biotech Stocks at the Cutting Edge of Drug Delivery (MDCX, RNA, NBTX, ARWR)September 18, 2025 | theglobeandmail.comNanobiotix S.A. (NBTX) Discusses on New Phase 1 Results In Metastatic Melanoma ConferenceSeptember 18, 2025 | seekingalpha.comNanobiotix S.A. (NBTX) Discusses On New Phase 1 Results In Metastatic Melanoma Conference (Transcript)September 18, 2025 | seekingalpha.comNanobiotix (NASDAQ:NBTX) Reaches New 12-Month High - Here's WhySeptember 18, 2025 | marketbeat.comNanobiotix soars on positive phase 1 results for JNJ-1900 in melanomaSeptember 18, 2025 | msn.comNanobiotix announces new results from JNJ-1900 studySeptember 17, 2025 | msn.comNANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary ...September 17, 2025 | finance.yahoo.comNANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1September 17, 2025 | globenewswire.comNanobiotix (NASDAQ:NBTX) Shares Up 5.7% - What's Next?September 14, 2025 | marketbeat.comNanobiotix to Present at H.C. Wainwright Investment ConferenceSeptember 5, 2025 | theglobeandmail.com Get Nanobiotix News Delivered to You Automatically Sign up to receive the latest news and ratings for NBTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NBTX Media Mentions By Week NBTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NBTX News Sentiment▼0.590.50▲Average Medical News Sentiment NBTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NBTX Articles This Week▼32▲NBTX Articles Average Week Get the Latest News and Ratings for NBTX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Nanobiotix and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Akero Therapeutics News Today Crinetics Pharmaceuticals News Today Jyong Biotech News Today NewAmsterdam Pharma News Today Kymera Therapeutics News Today Scholar Rock News Today Viking Therapeutics News Today Mirum Pharmaceuticals News Today Lantheus News Today ADMA Biologics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NBTX) was last updated on 10/22/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredWhat Wall Street Won’t Say Out LoudDiscover the 7 key indicators before everyone else doesAmerican Alternative | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredTrump cannot stop this trainThe Nobel Committee just confirmed what free-market thinkers have long argued — that true wealth isn’t built t...Porter & Company | SponsoredElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nanobiotix S.A. - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Nanobiotix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
